Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Xu
Quanyun A
QA
Clinical Pharmaceutics Research, Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Trissel
Lawrence A
LA
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D000077143:Docetaxel; D004338:Drug Combinations; D004355:Drug Stability; D007275:Injections, Intravenous / Q000379:methods; D007546:Isoquinolines / Q000008:administration & dosage / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry*; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage / Q000737:chemistry*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000737:chemistry*; D043823:Taxoids / Q000008:administration & dosage / Q000737:chemistry*
D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D043823:Taxoids; D000077143:Docetaxel; D000077924:Palonosetron; D017239:Paclitaxel